# Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma

> **NCT00287872** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 30 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** bortezomib
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00287872
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00287872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00287872, "Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT00287872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*